Pluvicto 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0012 
Minor change in labelling or package leaflet not 
27/11/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0011 
B.I.a.4.b - Change to in-process tests or limits 
20/11/2023 
n/a 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
PSUSA/11031
Periodic Safety Update EU Single assessment - 
26/10/2023 
n/a 
PRAC Recommendation - maintenance 
/202303 
lutetium (177LU) vipivotide tetraxetan 
N/0009 
Minor change in labelling or package leaflet not 
18/10/2023 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IB/0008/G 
This was an application for a group of variations. 
20/09/2023 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
II/0003 
B.I.a.1.b - Change in the manufacturer of AS or of a 
13/07/2023 
n/a 
starting material/reagent/intermediate for AS - 
Introduction of a manufacturer of the AS supported 
by an ASMF 
IB/0006/G 
This was an application for a group of variations. 
06/07/2023 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
IB/0002/G 
This was an application for a group of variations. 
11/05/2023 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.I.c.3.z - Changes in the test procedure for the 
immediate packaging of AS - Other variation 
IB/0004/G 
This was an application for a group of variations. 
19/04/2023 
Annex II, 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
Labelling and 
PL 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.II.b.1.f - Replacement or addition of a 
manufacturing site for part or all of the 
manufacturing process of the FP - Site where any 
manufacturing operation(s) take place, except batch 
release, batch control, and secondary packaging, for 
sterile medicinal products (including those that are 
aseptically manufactured) excluding biological/ 
immunological medicinal products 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
N/0001 
Minor change in labelling or package leaflet not 
30/01/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 4/4 
 
 
 
 
 
 
 
 
 
 
 
